Rise and shine, everyone, another busy day is on the way. We can tell because the short person made a successful, but harried, last-minute maneuver to arrive at the local schoolhouse on time and the official mascots are furiously fertilizing the frigid Pharmalot campus grounds. As for us, we are engaged in our usual routine of foraging for interesting items. On that note, here is a new batch. We hope your day is simply smashing and, as always, please do keep us in mind when something fascinating occurs …
Roche (RHHBY) racked up a third trial win for using its Tecentriq medicine in combination with other cancer drugs, a boost for the company as it seeks to muscle in on space dominated by Merck (MRK) and Bristol-Myers Squibb (BMY), Reuters explains. A late-stage study demonstrated Tecentriq mixed with carboplatin and Abraxane cut risk of disease worsening or death, compared with chemo alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer. Roche hopes to be the first to win regulatory approval for an immunotherapy combination against this form of lung cancer. There was no impact on overall survival so far, the other primary endpoint, and Roche says it is continuing the study as planned.
About the Author Reprints
